DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The investigators seek to assess the effect of pre-operative and continued post-operative
corticosteroid use on pain, patient preference, visual outcomes, and change in objective
quantifiable biological parameters in patients undergoing bilateral cataract surgery with
premium intraocular lens implantation with or without baseline ocular surface disease.
Patient's first eye scheduled for surgery will receive an intracanalicular insertion of
DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye). The
fellow-eye will receive topical prednisolone acetate 1% (tapering schedule of QID, TID, BID,
QD over 30 days). The fellow-eye design in n=30 patients (60 eyes) allows for balance in
patient baseline demographic and systemic characteristics.